Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE ME IAA. Issue 7 (24th February 2013)

• Record Type: Journal Article
• Authors: Smith, J.; Nazare, J.‐A.; Borel, A.‐L.; Aschner, P.; Barter, P. J.; Van Gaal, L.; Matsuzawa, Y.; Kadowaki, T.; Ross, R.; Brulle‐Wohlhueter, C.; Alméras, N.; Haffner, S. M.; Balkau, B.; Després, J.‐P.
• Is Part Of: Diabetes, obesity & metabolism. Volume 15:Issue 7(2013:Jul.)
• Page Start: 629
• Page End: 641
• Publication Date: 2013-02-24
• Subjects: Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12075
• Languages: English
• ISSNs: 1462-8902

Abstract

<abstract abstract-type="main"> <title>ABSTRACT</title> <sec id="dom12075-sec-0001" sec-type="section"> <title>Aim</title> <p>Visceral adipose tissue (VAT) and liver fat (LF) are strongly associated with type 2 diabetes. It is not known, however, how diabetes treatment and/or risk factor management modulates the association between VAT, LF and diabetes. The aim was to determine the level of VAT and LF in patients with type 2 diabetes according to their treatment status and achievement of the American Diabetes Association's (ADA) diabetes management goals.</p> </sec> <sec id="dom12075-sec-0002" sec-type="section"> <title>Methods</title> <p>We performed a cross‐sectional analysis of the baseline data of the International Study of the Prediction of Intra‐Abdominal Adiposity and its Relationship with Cardiometabolic risk/Intra‐Abdominal Adiposity (INSPIRE ME IAA), a 3‐year prospective cardiometabolic imaging study conducted in 29 countries. Patients (n = 3991) were divided into four groups: (i) those without type 2 diabetes (noT2D n = 1003 men, n = 1027 women); (ii) those with type 2 diabetes but not treated with diabetes medications (T2Dnomeds n = 248 men, n = 198 women); (iii) those with type 2 diabetes and treated with diabetes medications but not yet using insulin (T2Dmeds‐ins n = 591 men, n = 484 women) and (iv) those with type 2 diabetes and treated with insulin (T2Dmeds+ins n = 233 men, n = 207 women). Abdominal and liver adiposity were measured by computed tomography.</p> </sec> <sec id="dom12075-sec-0003" sec-type="section"> <title>Results</title> <p>Fewer patients with high VAT or LF achieved the ADA's goals for high‐density lipoprotein cholesterol (HDL‐C) or triglycerides compared to patients with low VAT or LF. Visceral adiposity (p = 0.02 men, p = 0.003 women) and LF (p = 0.0002 men, p = 0.0004 women) increased among patients who met fewer of the ADA treatment criteria, regardless of type 2 diabetes treatment.</p> </sec> <sec id="dom12075-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Residual cardiometabolic risk exists among patients with type 2 diabetes characterized by elevated VAT and LF.</p> </sec> </abstract>